Upstream / Downstream

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

To Purchase # 8928SC

8928SC 10 µg (With Carrier) $179.00
8928SF 10 µg (Carrier Free) $179.00
8928LC 50 µg (With Carrier) $529.00
8928LF 50 µg (Carrier Free) $529.00
$ 0. 00

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Source / Purification

Recombinant human IL-17A (hIL-17A) Ile20-Ala155 (Accession #NP_002181) was expressed in human 293 cells at Cell Signaling Technology.

Product Description

Purity:

>97% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIL-17A. All lots are greater than 97% pure


Molecular Formula:

Recombinant hIL-17A contains no "tags" and the nonglycosylated protein has a calculated MW of 15,535. DTT-reduced protein migrates as a 16-24 kDa polypeptide. Heterogeneity in SDS PAGE is due to glycosylation. The non-reduced cystine-linked homodimer migrates as a 28-37 kDa protein. The expected amino-terminal IVKAG of recombinant hIL-17A was verified by amino acid sequencing.


Bioactivity:

The bioactivity of recombinant hIL-17A was determined by its ability to induce IL-6 production by primary human fibroblasts. The ED50 of each lot is between 1.5 - 3.5 ng/ml.


Endotoxin:

Less than 0.01 ng endotoxin/1 μg hIL-17A.


Product Usage Information

Formulation:

With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hIL-17A. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.


Storage: Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

IL-17A is a cystine-linked homodimeric pro-inflammatory cytokine produced by Th17 cells, a distinct CD4+ T cell lineage (1,2). IL-17A stimulates the production of the pro-inflammatory cytokines IL-1β, TNF-α, and IL-6. IL-17A also induces production of the neutrophil chemoattractants IL-8, CXCL1, and CXCL6 thereby bridging adaptive and innate immunity (1,2). IL-17A is intimately involved in mucosal immunity against bacterial infections (1,3) and has a putative role in some autoimmune disorders (1,4). IL-17A effects appear to be exerted primarily through binding to the IL-17RA (5). IL-17A binding induces production of cytokines, chemokines and other proteins through activation of the Erk1/2 MAP kinase, PI3K/Akt, p38, and NF-κB pathways (3,4, 6). Phosphorylation of some Jaks and Stats has been observed.


1.  Kolls, J.K. and Lindén, A. (2004) Immunity 21, 467-76.

2.  Liang, S.C. et al. (2006) J Exp Med 203, 2271-9.

3.  Dubin, P.J. and Kolls, J.K. (2008) Immunol Rev 226, 160-71.

4.  Zrioual, S. et al. (2009) J Immunol 182, 3112-20.

5.  Wright, J.F. et al. (2008) J Immunol 181, 2799-805.

6.  Rahman, M.S. et al. (2006) J Immunol 177, 4064-71.


Entrez-Gene Id 3605
Swiss-Prot Acc. Q16552


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.